FP-045 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 285 | Fanconi anemia | 1 |
285. Fanconi anemia
Clinical trials : 59 / Drugs : 118 - (DrugBank : 32) / Drug target genes : 31 - Drug target pathways : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04522375 (ClinicalTrials.gov) | October 2021 | 3/8/2020 | Phase I/II Study of FP-045 in Patients With Fanconi Anemia | A Phase 1/2 Multicenter, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of FP-045 in Patients With Fanconi Anemia | Fanconi Anemia | Drug: FP-045 | Foresee Pharmaceuticals Co., Ltd. | NULL | Not yet recruiting | 3 Years | 18 Years | All | 56 | Phase 1/Phase 2 | NULL |